Advertisement
Advertisement
U.S. Markets open in 9 hrs 8 mins
Advertisement
Advertisement
Advertisement
Advertisement

Organovo Holdings, Inc. (ONVO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.8300+0.0600 (+3.39%)
At close: 04:00PM EDT
1.9000 +0.07 (+3.83%)
After hours: 07:30PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.7700
Open1.7900
Bid1.8300 x 1200
Ask1.9700 x 1300
Day's Range1.7700 - 1.8650
52 Week Range1.7300 - 9.6200
Volume12,343
Avg. Volume24,709
Market Cap15.931M
Beta (5Y Monthly)0.50
PE Ratio (TTM)N/A
EPS (TTM)-1.3970
Earnings DateFeb 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Organovo Achieves 3D Tissue Model for Crohn’s Disease

    SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional (3D) biology company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announces that it has successfully advanced its first inflammatory bowel disease (IBD) model to the next step of target discovery and validation for Crohn’s disease. Based on its internal data and scientific results, the company believes that its first IBD mo

  • Motley Fool

    Why Organovo Holdings, Inc. Stock Soared 49.7% This Week

    The company's licensing agreement with a Swedish company means an infusion of some much-needed cash for Organovo.

  • GlobeNewswire

    UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

    SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO (OTCPK: CLLKF, Nasdaq Stockholm: BICO.ST) announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo’s foundational patent portfolio in 3D bioprinting. Founded in 2016, BICO (formerly Cellink) is the leading bio convergence company in the world. Cellink continues to operate as a wholly owned division of BICO. Organovo exclusively licensed early bioprinting

Advertisement
Advertisement